Ebola virus vaccine - Hawaii Biotech/Soligenix/University of Hawaii
Alternative Names: Ebola subunit vaccine - Soligenix; SuVax™Latest Information Update: 02 May 2024
At a glance
- Originator Hawaii Biotech; Soligenix; University of Hawaii
- Developer Soligenix; University of Hawaii
- Class Subunit vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Ebola virus infections
Most Recent Events
- 25 Apr 2024 Soligenix receives notice of intent to grant additional patents based on its patent compositions and methods of manufacturing trivalent filovirus vaccines in the United Kingdom and South Africa, with other international jurisdictions pending
- 11 Apr 2024 Ebola virus vaccine receives Orphan Drug status for Ebola virus infections (Prevention) in USA
- 08 Nov 2022 Soligenix receives patent allowance for compositions and methods of manufacturing of Trivalent filovirus vaccines in USA